CHARACTERISTICS AND MANAGEMENT OF MIGRAINE PATIENTS WHO HAVE FAILED PRIOR PREVENTIVE TREATMENT IN PORTUGAL

被引：0
|
作者：
Silva, C. [1 ]
Vo, P. [2 ]
Carboni, V [3 ]
Quintana, R. [4 ]
Monge, S. [1 ]
Laires, P. A. [1 ]
机构：
[1] Novartis Farma, Porto Salvo, Portugal
[2] Novartis Pharma AG, Basel, Switzerland
[3] GfK Hlth, Basel, Switzerland
[4] GfK, Madrid, Spain
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2106
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND141
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [21] Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Shiffman, ML
    Di Bisceglie, AM
    Lindsay, KL
    Morishima, C
    Wright, EC
    Everson, GT
    Lok, AS
    Morgan, TR
    Bonkovsky, HL
    Lee, WM
    Dienstag, JL
    Ghany, MG
    Goodman, ZD
    Everhart, JE
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : 1015 - 1023
  • [22] Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study
    Winner, Paul K.
    Freeman, Marshall C.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Ortega, Mario
    [J]. ANNALS OF NEUROLOGY, 2019, 86 : S168 - S169
  • [23] Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study
    Winner, P. K.
    Freeman, M. C.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    [J]. HEADACHE, 2019, 59 : 118 - 119
  • [24] Long-term efficacy of fremanezumab in chronic and episodic migraine patients who failed at least one prior migraine preventive medication: results of a 1-year study
    Winner, Paul K.
    Freeman, Marshall C.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Blaiss, Cory
    [J]. CEPHALALGIA, 2019, 39 : 36 - 37
  • [25] Efficacy of galcanezumab in patients who failed prior preventive treatments for migraine: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
    Dell'Agnello, Grazia
    Tockhorn-Heidenreich, Antje
    Zhang, Qi
    Ruff, Dustin D.
    Pearlman, Eric M.
    Aurora, Sheena K.
    Ford, Janet H.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [26] Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
    Ronan Mahon
    Andrea Lang
    Pamela Vo
    Jasper Huels
    Philip Cooney
    Andriy Danyliv
    Umakanth Vudumula
    Sreelatha Vadapalle
    Farooq Maniyar
    Peter J. Goadsby
    [J]. PharmacoEconomics, 2021, 39 : 357 - 372
  • [27] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
    McAllister, P.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    [J]. HEADACHE, 2019, 59 : 119 - 119
  • [28] Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
    Mahon, Ronan
    Lang, Andrea
    Vo, Pamela
    Huels, Jasper
    Cooney, Philip
    Danyliv, Andriy
    Vudumula, Umakanth
    Vadapalle, Sreelatha
    Maniyar, Farooq
    Goadsby, Peter J.
    [J]. PHARMACOECONOMICS, 2021, 39 (03) : 357 - 372
  • [29] Patient Demographics and Baseline Characteristics from the Phase 3b LIBERTY Study of Erenumab in Patients with Episodic Migraine Who Failed ≥2 Preventive Migraine Treatments
    Goadsby, P. J.
    Lanteri-Minet, M.
    Ferrari, M.
    Wen, S.
    Hours-Zesiger, P.
    Klatt, J.
    [J]. HEADACHE, 2018, 58 : 181 - 182
  • [30] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
    Brandes, J.
    Smith, T. R.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    [J]. HEADACHE, 2019, 59 : 119 - 120
12345